lyb002

Vaccineexperimental

Clinical trial activity

2 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Apr 25, 2023 (NCT05928468)

Timeline

2020s

  1. Jan 1, 2023

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • SARS-CoV-2Immunity, active

    immunity, active - SARS-CoV-2

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06167915Phase 1Dec 26, 2023Government of China, Sichuan University
NCT05928468Early Phase 1 (Phase 1)Apr 25, 2023Government of China, North Sichuan Medical University
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of ChinaGovernment2212023
North Sichuan Medical UniversityAcademic/Hospital1012023
Sichuan UniversityAcademic/Hospital1012023
3 organizations
Page 1 / 1